Collectively, these data establish that pharmacological modulation of the PAR-2/ERK/TNF-α axis by statins redirects inflammatory colorectal cancer cells from survival toward programmed cell death, with rosuvastatin demonstrating consistently greater potency than atorvastatin. This evidence concerns the gene TNF and colorectal cancer.